OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- Resource Type
- Article
- Source
- In
Annals of Oncology April 2019 30(4):558-566 - Subject
- Language
- ISSN
- 0923-7534